Abstract
Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised to treatment with Tesofensine 0.25, 0.5, or 1.0 mg, or placebo daily for 24 weeks. Treatment with Tesofensine resulted in a mean weight reduction of 4.5, 9.2 and 10.6% higher than that of placebo for 0.25, 0.5 and 1.0 mg, respectively. Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of safety and efficacy of 0.5 mg Tesofensine need confirmation in phase III trials.
Publication types
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Anti-Obesity Agents / adverse effects
-
Anti-Obesity Agents / therapeutic use*
-
Body Composition / drug effects*
-
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
-
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
-
Double-Blind Method
-
Female
-
Humans
-
Male
-
Middle Aged
-
Obesity / drug therapy*
-
Time Factors
-
Treatment Outcome
-
Weight Loss
-
Young Adult
Substances
-
Anti-Obesity Agents
-
Bridged Bicyclo Compounds, Heterocyclic
-
Tesofensine